SCHEDULE 13G/A: Vanguard Group Discloses 10.03% Passive Stake in Alnylam Pharmaceuticals

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of March 31, 2025.

Summary

• The Vanguard Group beneficially owns an aggregate of 13,056,605 shares of Alnylam Pharmaceuticals Inc. Common Stock.
• This ownership represents 10.03% of the class of securities.
• Vanguard holds sole voting power over 0 shares and shared voting power over 100,382 shares.
• Vanguard holds sole dispositive power over 12,722,314 shares and shared dispositive power over 334,291 shares.
• The filing is an Amendment No. 9 to the Schedule 13G, indicating ongoing reporting of their stake.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership, providing factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral disclosure of a passive investment stake.

Positives

• The disclosure of a significant 10.03% stake by a major institutional investor like The Vanguard Group can be viewed as a vote of confidence in Alnylam Pharmaceuticals Inc. by a large, passive investment manager.
• The passive nature of the investment, as certified by Vanguard, suggests stability and a long-term holding strategy rather than an activist intent.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Alnylam Pharmaceuticals Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Ashley Grim, Head of Global Fund Administration for The Vanguard Group)

Industry Context

The Vanguard Group is one of the world's largest investment management companies, primarily known for its index funds and ETFs. Their significant stake in Alnylam Pharmaceuticals Inc., a biotechnology company, is typical of a broad market or sector-specific index fund's holdings, reflecting the company's inclusion in relevant market indices rather than a specific active investment thesis on Alnylam's individual performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a large, passive investment presence in the company's stock.

Key Dates

Keywords

Alnylam Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, institutional investor, common stock, SEC filing, passive investment